RegulatoryRegulatoryPHN-03072026-10-19 11:19 CT
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
Source · FDA press releases
TLDR
The FDA granted accelerated approval for a new use of Jemperli (dostarlimab-gxly) in certain patients with locally advanced rectal cancer. The agency says the immunotherapy may allow some patients to avoid chemotherapy, radiation and surgery.
01—Key points
- 01The action is an accelerated approval for a new use of Jemperli.
- 02The FDA describes a potential to avoid common treatments with lasting effects on daily life.
- 03The excerpt provides no trial results or detailed eligibility criteria.
Why it matters Editorial
The FDA says this approval may allow certain patients with rectal cancer to avoid treatments that can have lasting effects on daily life.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.